Status:
COMPLETED
Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy
Lead Sponsor:
Chang-Ming Huang, Prof.
Conditions:
Gastric Cancer
Eligibility:
All Genders
Brief Summary
HMDLS, based on hematological markers, could effectively distinguish the long-term efficacy of AGC patients after NAT. The predictive performance of nomogram-HMDLS was better than ypTNM stage, achievi...
Detailed Description
In this research, we incorporated a total of 320 patients from the Union Hospital of Fujian Medical University to form the training cohort (TC). Additionally, we included 122 patients from four distin...
Eligibility Criteria
Inclusion
- (1) AGC with clinical stage T2-4NxM0 (cT2-4NxM0) before NAT, (2) no history of other malignant tumors, distant metastases or invasion of adjacent organs, and (3) patients who underwent radical gastrectomy after receiving NAT.
Exclusion
- (1) history of upper abdominal surgery (except for the laparoscopic cholecystectomy), (2) history of upper abdominal radiotherapy, (3) emergency surgery, or palliative surgery, (4) continuous use of medications such as anticoagulant, antiplatelet, and leukocyte-boosting drugs that significantly affect hematological markers during therapy, and (5) incomplete clinical and follow-up data.
Key Trial Info
Start Date :
June 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 26 2024
Estimated Enrollment :
442 Patients enrolled
Trial Details
Trial ID
NCT06573307
Start Date
June 10 2024
End Date
August 26 2024
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastric Surgery， Fujian Medical University Union Hospital
Fuzhou, Fujian, China